Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer

详细信息    查看全文

• 作者：Arne R.M. van der Bilt ; Elisabeth G.E. de Vries ; Steven de Jong ; Hetty Timmer-Bosscha ; Ate G.J. van der Zee ; Anna K.L. Reyners
• 关键词：Ovarian cancer ; Angiogenesis ; Antiangiogenic therapy ; Bevacizumab ; Tyrosine kinase inhibition ; VEGF-Trap ; Patient selection
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2012
• 出版时间：November, 2012
• 年：2012
• 卷：84
• 期：2
• 页码：224-242
• 全文大小：706 K

文摘

Despite efforts to improve chemotherapeutic efficacy in epithelial ovarian cancer, outcome for patients with advanced disease has remained unchanged since the introduction of standard carboplatin and paclitaxel. Interest has therefore shifted toward molecularly targeted therapies that interfere with important features of ovarian carcinogenesis, such as angiogenesis. Several angiogenesis inhibitors, targeting vascular endothelial growth factor (VEGF) ligands (bevacizumab, VEGF-Trap) or their receptors (VEGFR-targeted tyrosine kinase inhibitors) have been clinically evaluated. These agents demonstrated efficacy in phase II clinical trials. Results from phase III trials, in which bevacizumab was added to standard frontline chemotherapy, show a modest effect. Although the initial expectations for angiogenesis inhibitors have been tempered, further research is warranted to define their precise place in the treatment of ovarian cancer. This review summarizes the performed and ongoing studies with regard to angiogenesis inhibitors in ovarian cancer, and the available data on biomarkers for response prediction. Preclinical studies evaluating alternative angiogenesis inhibitors will also be discussed.